Karni A - Search Results

1

Real-World experience with efgartigimod in patients with myasthenia gravis.

Fuchs L, Shelly S, Vigiser I, Kolb H, Regev K, Schwartzmann Y, Vaknin-Dembinsky A, Dori A, Karni A. Fuchs L, et al. Among authors: karni a. J Neurol. 2024 Jun;271(6):3462-3470. doi: 10.1007/s00415-024-12293-5. Epub 2024 Mar 25. J Neurol. 2024. PMID: 38528163

2

Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor.

Karni A, Zisman E, Katz-Levy Y, Paas-Rozner M, Dayan M, Brautbar C, Abramsky O, Sela M, Mozes E. Karni A, et al. Neurology. 1997 Jun;48(6):1638-42. doi: 10.1212/wnl.48.6.1638. Neurology. 1997. PMID: 9191780

3

Effects of sex hormones on experimental autoimmune myasthenia gravis.

Leker RR, Karni A, Brenner T, Weidenfeld J, Abramsky O. Leker RR, et al. Among authors: karni a. Eur J Neurol. 2000 Mar;7(2):203-6. doi: 10.1046/j.1468-1331.2000.00042.x. Eur J Neurol. 2000. PMID: 10809942

4

Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis.

Urshansky N, Mausner-Fainberg K, Auriel E, Regev K, Farhum F, Karni A. Urshansky N, et al. Among authors: karni a. J Neurol Sci. 2010 Aug 15;295(1-2):31-7. doi: 10.1016/j.jns.2010.05.019. Epub 2010 Jun 11. J Neurol Sci. 2010. PMID: 20541775

5

Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.

Urshansky N, Mausner-Fainberg K, Auriel E, Regev K, Bornstein NM, Karni A. Urshansky N, et al. Among authors: karni a. J Neuroimmunol. 2011 Mar;232(1-2):171-8. doi: 10.1016/j.jneuroim.2010.10.007. Epub 2010 Nov 26. J Neuroimmunol. 2011. PMID: 21111488

6

Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance.

Auriel E, Regev K, Dori A, Karni A. Auriel E, et al. Among authors: karni a. Muscle Nerve. 2011 Jun;43(6):893-4. doi: 10.1002/mus.22077. Muscle Nerve. 2011. PMID: 21607970

7

Low and dysregulated production of follistatin in immune cells of relapsing-remitting multiple sclerosis patients.

Urshansky N, Mausner-Fainberg K, Auriel E, Regev K, Karni A. Urshansky N, et al. Among authors: karni a. J Neuroimmunol. 2011 Sep 15;238(1-2):96-103. doi: 10.1016/j.jneuroim.2011.08.003. Epub 2011 Aug 31. J Neuroimmunol. 2011. PMID: 21880375

8

Seasonal and H1N1v influenza vaccines in MS: safety and compliance.

Auriel E, Gadoth A, Regev K, Karni A. Auriel E, et al. Among authors: karni a. J Neurol Sci. 2012 Mar 15;314(1-2):102-3. doi: 10.1016/j.jns.2011.10.013. Epub 2011 Nov 5. J Neurol Sci. 2012. PMID: 22056469

9

Role of immunosuppressive therapy for the treatment of multiple sclerosis.

Stankiewicz JM, Kolb H, Karni A, Weiner HL. Stankiewicz JM, et al. Among authors: karni a. Neurotherapeutics. 2013 Jan;10(1):77-88. doi: 10.1007/s13311-012-0172-3. Neurotherapeutics. 2013. PMID: 23271506 Free PMC article. Review.

10

High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis.

Levy YA, Fainberg KM, Amidror T, Regev K, Auriel E, Karni A. Levy YA, et al. Among authors: karni a. J Neuroimmunol. 2013 Apr 15;257(1-2):82-9. doi: 10.1016/j.jneuroim.2013.01.012. Epub 2013 Mar 7. J Neuroimmunol. 2013. PMID: 23466131

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters